Current Roles

Employees:
4
Revenue:
$310k
About
Inspire has developed a lung tropic AAV gene therapy platform that has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types in disease-relevant animal models. We are currently pursing initiation of a Proof-of-Concept clinical trial for a lethal neonatal lung disease with short time to data readout and success of therapy. The platform can then be applied to Cystic Fibrosis and other monogenic lung diseases.
Inspire Biotherapeutics Address
N/A
null, null
Inspire Biotherapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.